Vetenskapliga artiklar

  • Feeding transgenic plants that express a tolerogenic fusion protein effectively protects against arthritis.
    Hansson C, Schön K, Kalbina I, Strid Å, Andersson S, Bokarewa MI, Lycke NY.
    Plant Biotechnol J. 2015 Sep.
  • Recent progress in mucosal vaccine development: potential and limitations.
    Lycke N.
    Nat Rev Immunol. 2012 Jul. Review.
  • ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization.
    Hasselberg A, Ekman L, Yrlid LF, Schön K, Lycke NY.
    J Immunol. 2010 Mar.
  • Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis.
    Hasselberg A, Schön K, Tarkowski A, Lycke N.
    Arthritis Rheum. 2009 Jun.
  • From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.
    Lycke N.
    Immunol Lett. 2005 Mar.
  • ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci. 2004 Dec.

Patent

  • New compositions and methods for treatment of autoimmune and allergic diseases
    WO2012057671A1.pdf